

chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim ¹⁸33 to a subject in need of such treatment.

¹⁸45. A method of treating according to claim ¹⁷44 wherein the compressed solid dosage form is orally administered to the subject.

⁹46. A method of treating hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, stroke, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim ¹¹38 to a subject in need of such treatment.

²⁰47. A method of treating according to claim ¹⁹46 wherein the compressed solid dosage form is orally administered to the subject.

²¹48. A method of treating hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, stroke, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim ¹³40 to a subject in need of such treatment.

²⁰49. A method of treating according to claim ²¹48 wherein the compressed solid dosage form is orally administered to the subject.

REMARKS

Examination of this application and early allowance are respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807

Diane Tso
Diane Tso
Attorney for Applicants
Reg. No. 46,012

Date: August 13, 2001